Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform treatment of cancer and autoimmune diseases by developing allogeneic, iPSC-derived NK and T cell therapies.
PRESS RELEASES + EVENTS
view all
January 21, 2025
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
– Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated…
November 26, 2024
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
About us
We are building an industry leading allogeneic iPSC-derived cell therapy platform for cancer and autoimmune diseases.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
